← Back to headlines
BTIG Reaffirms Buy Rating for Praxis Precision Medicines
BTIG has reiterated its 'Buy' rating for Praxis Precision Medicines (PRAX), indicating continued confidence in the company's stock performance and prospects.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
